Phoenix Bio

R&D OVERVIEW

R&D OVERVIEW

Contribution of chimeric mice with a humanized liver to the evaluation of pharmacology, toxicity, and pharmacokinetics in drug discovery and development

    Sanoh, S. Ohta, S.

    Nihon Yakurigaku Zasshi. 2018;151(5):213-220

    Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure

      Teraoka, Y. Uchida, T. Imamura, M. Hiraga, N. Osawa, M. Kan, H. Saito, Y. Tsuge, M. Abe-Chayama, H. Hayes, C. N. Makokha, G. N. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

      J Gen Virol. 2018 Jun 19. doi: 10.1099/jgv.0.001091.

      Characterization of HBV integration patterns and timing in liver cancer and HBV-infected livers

        Furuta, M. Tanaka, H. Shiraishi, Y. Unida, T. mamura, M. Fujimoto, A. Fujita, M. Sasaki-Oku, A. Maejima, K. Nakano, K. Kawakami, Y. Arihiro, K. Aikata, H. Ueno, M. Hayami, S. Ariizumi, S. I. Yamamoto, M. Gotoh, K. Ohdan, H. Yamaue, H. Miyano, S. Chayama, K. Nakagawa, H.

        Oncotarget. 2018 May 18;9(38):25075-25088.

        The whole transcriptome effects of the PPARalpha agonist fenofibrate on livers of hepatocyte humanized mice

          de la Rosa Rodriguez, M. A. Sugahara, G. Hooiveld, Gjej Ishida, Y. Tateno, C. Kersten, S.

          BMC Genomics. 2018 Jun 7;19(1):443. doi: 10.1186/s12864-018-4834-3.

          Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice

            Teraoka, Y. Uchida, T. Imamura, M. Osawa, M. Tsuge, M. Abe-Chayama, H. Hayes, C. N. Makokha, G. N. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

            Biochem Biophys Res Commun. 2018 Jun 2;500(2):152-157.

            Inhibitory effects of drugs on the metabolic activity of mouse and human aldehyde oxidases and influence on drug-drug interactions

              Takaoka, N. Sanoh, S. Okuda, K. Kotake, Y. Sugahara, G. Yanagi, A. Ishida, Y. Tateno, C. Tayama, Y. Sugihara, K. Kitamura, S. Kurosaki, M. Terao, M. Garattini, E. Ohta, S.

              Biochem Pharmacol. 2018 Apr 17;154:28-38.

              FXR Activation by Obeticholic Acid or Non-Steroidal Agonists Induces a Human-Like Lipoprotein Cholesterol Change in Mice with Humanized Chimeric Liver

                Papazyan, R. Liu, X. Liu, J. Dong, B. Plummer, E. M. Lewis, R. D., 2nd Roth, J. D. Young, M. A.

                J Lipid Res. 2018 Mar 20. pii: jlr.M081935. doi: 10.1194/jlr.M081935.

                Acute HBV infection in humanized chimeric mice has multiphasic viral kinetics

                  Ishida, Y. Chung, T. L. Imamura, M. Hiraga, N. Sen, S. Yokomichi, H. Tateno, C. Canini, L. Perelson, A. S. Uprichard, S. L. Dahari, H. Chayama, K.

                  Hepatology. 2018 Mar 23. doi: 10.1002/hep.29891.

                  Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection

                    Rolt, A. Le, D. Hu, Z. Wang, A. Q. Shah, P. Singleton, M. Hughes, E. Dulcey, A. E. He, S. Imamura, M. Uchida, T. Chayama, K. Xu, X. Marugan, J. J. Liang, T. J.

                    J Infect Dis. 2018 Jan 24. pii: 4823490. doi: 10.1093/infdis/jiy039.

                    A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage

                      Reddy, B. U. Mullick, R. Kumar, A. Sharma, G. Bag, P. Roy, C. L. Sudha, G. Tandon, H. Dave, P. Shukla, A. Srinivasan, P. Nandhitha, M.Srinivasan, N. Das, S.

                      Antiviral Res. 2017 Dec 7;150:47-59.